

## KEBILIDI™ Prescription Start Form



Contact us: 1-844-4PTCCARES (1-844-478-2227) Fax completed form to: 1-877-204-2180

- > Step 1: Complete ALL fields on this form including the prescription to prevent delays in processing.
- > Step 2: If possible, obtain patient or guardian's signature for the Patient Authorization and PTC Cares™ Program Participation.
- > Step 3: Fax this form, along with copies of both sides of insurance and prescription benefit cards, to PTC Cares<sup>TM</sup> at 1-877-204-2180.

PATIENT INFORMATION								
Patient Name (First, MI, Last)	Date	Date of Birth / / 🗆 Male 🛭			□ Female			
Guardian/Caregiver's Name	Relationship							
Address	City			State	ZIP			
Home Phone	□ OK to leave message	Mobile			□ OK to	□ OK to leave message		
Preferred Contact Number □ Home	Best time to reach me ☐ Morning ☐ Afternoon ☐ Evening				ening			
Email Address	Primary Language □ English □ Spanish □ Other							
INSURANCE INFORMATION	Daine ann Leasunan an				C			
Insurance Name	Primary Insurance	!			Secondary In		nsurance	
Policy Number								
Group Number								
Phone Number								
Policyholder Name								
Rx Member ID								
Rx BIN or PCN (if applicable)								
Rx Group ID								
health plans to disclose personal and health and contractors including, but not limited to to use such information to: 1) determine ben with support services for KEBILIDI™ (eladoc information or materials related to KEBILIDI™ patient services such as education, training, information pursuant to this authorization. P'this information only for the purposes describ and state privacy laws may not prevent PTC it receives for the purposes described in this authorization will have no impact on my eligi PTC Cares™ program. I understand that I hav 7231 or by mail to PTC Therapeutics, Inc. At revoked my authorization, PTC Therapeutics of the program for record keeping purposes termination is required by applicable state la Rights and Choices specific to California resic	Participation  In Authorization to share my health information related to my use or potential use, PTC's specialty pharmacy partners and autefit eligibility; 2) communicate with my healt agene exuparvovec-tneq); 4) contact me an five (eladocagene exuparvovec-tneq) or my releanurse and pharmacy support; and 7) I under TC Therapeutics will maintain the confidentic sed above or as permitted by law. However, It Therapeutics from further disclosing my information authorization or as required by law. I furthe billity to receive health plan benefits or treative the right to revoke this authorization at any tention: Compliance Officer, PTC Therapeutivention: Compliance Officer, PTC Therapeutivention longer disclose my information, except of my participation. I am entitled to a copy of the compliance of the compliance of my participation.	tion and participa se of KEBILIDI™ (ei chorize PTC Thera) hcare providers and leave messages evant medical concistand that my pholity of my persona inderstand that or mation. I understa er understand that ments from my hec time in the future, cs, 500 Warren Cotto the extent that of this authorization in surance and informariance and informaria en the surance and informaria en the surance and informaria en the surance and informaria care providers and providers	eladocage peutics, in dhealth about Ki ditions; 6) armacy mil and heance information that Fet I may realthcare; by submi or porate et action hon, which informati rmation I	ene exuparvover to agents, and in plans about be BILIDI™ (elada contact me about my receive rem lth information about my TTC Therapeutic fuse to sign this providers, but I vitting a written racenter Drive, Was been taken in expires 10 year on, please see a have provided a sign of the sign of	in-tneq) to PTC my pharmacie mefit, coverage cagene exup- cout the PTC C uneration in e in accordance is released b cs has agreed s authorizatic vill not have o in tice to PTC farren, NJ 070 ir reliance on the s from the da our privacy sto	Therapeut is or design e and media arvovec-tne arvovec-tne with its privace on this to only use on and that access to sup Therapeutic 159. I understie it is signe teement at Ecomplete ar	tics, Inc. and its agents ated treatment center cal care; 3) provide me arg; 5) provide me with ram, which may include a sharing and using my vacy policy and will use authorization, federal or disclose information my refusal to sign this poort services from the as via fax to 1-908-222-stand that after I have ation or administration by me (unless earlier PTCBio.com for Privacy and accurate to the best	
Patient/Guardian Signature								
Relationship		Do	ate					



Please see www.KEBILIDI.com for full Prescribing Information

**Contact us:** 1-844-4PTCCARES (1-844-478-2227)

Fax completed form to: 1-877-204-2180
Learn more at: www.KEBILIDI.com



## TO BE COMPLETED BY HEALTHCARE PROVIDER



Patient First Name		Patient Last Nar	Patient Last Name			Birth	/	/			
CLINICAL INFORMATION	/DIAGNOSIS										
Primary Diagnosis	Primary ICD-10										
Allergies	Cur	rent weight	□ lbs. □ kg.	g. Date weight obtained							
Other medications tried	1			ı							
Confirmed ICD-10 diagnosis: E	70.81 □ Yes □ N	0									
PRESCRIPTION INFORMA	TION										
PRESCRIPTION FOR KEBI		ene exuparvovec-t	nea)								
CRITERIA (ALL <u>must</u> be checked with supporting documentation included with submission)											
☐ Patient has confirmed AADC deficiency due to biallelic mutations in the DDC gene . Please include documentation of results.											
☐ Clinical note(s) describing m	edical need include	ed with fax to PTC <i>Car</i>	es <sup>TM</sup>								
Additional information											
☐ 1.8×10 <sup>11</sup> vector genomes (vg	) of eladocagene e	xuparvovec-tneg supp	olied as one single-o	dose vial that cont	ains 2.8×1	0 <sup>11</sup> vg					
Special instructions	<u> </u>										
PRESCRIBER INFORMATION	ON.										
Prescriber Name (First, Last)  Designated Treatment Center Name											
Address											
Phone	Fax	NPI#	City	DEA#		Tax ID#	Zip				
Office Contact Name	TGX	Phone		···		I Morning □Afternoon					
Office Contact Email		Dest time to	, contact L	21110111111	9 🗀 / 11	cerrioon					
Office Contact Lindii											
Physician Authorization*:  By signing the Start Form, I certify th necessity. I authorize the release of (including, but not limited to KEBILI authorize PTC Cares™ to initiate any health plans, to the extent not prohil	medical and/or other DI-dispensing pharmo de minimis authoriza bited. *NY Prescribe	patient information relocacies) to use and disclose tion processes from appli	ating to KEBILIDI ther as necessary for pric cable health plans, if r	apy to agents of PT r authorization proc needed, including the	C Therapeu essing and	itics, Inc., fulfillmen	and sei t of the	rvice providers prescription. I			
Prescriber Authorization Signature Dispense as Written (No Stamp Allowed)				Date							



Please see www.KEBILIDI.com for full Prescribing Information

**Contact us:** 1-844-4PTCCARES (1-844-478-2227)

Fax completed form to: 1-877-204-2180 Learn more at: www.KEBILIDI.com © 2024 PTC Therapeutics, Inc. All Rights Reserved. PTC  $Cares^{TM}$  is a trademark of PTC Therapeutics, Inc. KEBILIDI<sup>TM</sup> is a registered trademark of PTC Therapeutics, Inc. in the US and other countries. US-KEB-0201 | 12/24